Anti-phospholipid autoantibodies in human diseases

Rencai Qin; Haiqi Wu; Hui Guan; Chun Tang; Zhihua Zheng; Chong Deng; Chengshun Chen; Qinghua Zou; Liwei Lu; Kongyang Ma

doi:10.1016/j.clim.2023.109803

Anti-phospholipid autoantibodies in human diseases

Clin Immunol. 2023 Nov:256:109803. doi: 10.1016/j.clim.2023.109803. Epub 2023 Oct 19.

Authors

Rencai Qin¹, Haiqi Wu¹, Hui Guan¹, Chun Tang¹, Zhihua Zheng¹, Chong Deng², Chengshun Chen³, Qinghua Zou⁴, Liwei Lu⁵, Kongyang Ma⁶

Affiliations

¹ Shenzhen Key Laboratory for Systems Medicine in Inflammatory Diseases, Centre for Infection and Immunity Studies (CIIS), School of Medicine, The Seventh Affiliated Hospital, Shenzhen Campus of Sun Yat-Sen University, Shenzhen, Guangdong 518107, China.
² Department of Pathology and Shenzhen Institute of Research and Innovation, The University of Hong Kong, Hong Kong 999077, China.
³ Department of Rheumatology and Immunology, First Affiliated Hospital of Army Medical University, Chongqing, China.
⁴ Department of Rheumatology and Immunology, First Affiliated Hospital of Army Medical University, Chongqing, China. Electronic address: zouqinghua318@tmmu.edu.cn.
⁵ Department of Pathology and Shenzhen Institute of Research and Innovation, The University of Hong Kong, Hong Kong 999077, China. Electronic address: liweilu@hku.hk.
⁶ Shenzhen Key Laboratory for Systems Medicine in Inflammatory Diseases, Centre for Infection and Immunity Studies (CIIS), School of Medicine, The Seventh Affiliated Hospital, Shenzhen Campus of Sun Yat-Sen University, Shenzhen, Guangdong 518107, China. Electronic address: makyang@mail.sysu.edu.cn.

PMID: 37821073
DOI: 10.1016/j.clim.2023.109803

Abstract

Anti-phospholipid autoantibodies are a group of antibodies that can specifically bind to anionic phospholipids and phospholipid protein complexes. Recent studies have reported elevated serum anti-phospholipid autoantibody levels in patients with antiphospholipid syndrome, systemic lupus erythematosus, rheumatoid arthritis, metabolic disorders, malaria, SARS-CoV-2 infection, obstetric diseases and cardiovascular diseases. However, the underlying mechanisms of anti-phospholipid autoantibodies in disease pathogenesis remain largely unclear. Emerging evidence indicate that anti-phospholipid autoantibodies modulate NETs formation, monocyte activation, blockade of apoptotic cell phagocytosis in macrophages, complement activation, dendritic cell activation and vascular endothelial cell activation. Herein, we provide an update on recent advances in elucidating the effector mechanisms of anti-phospholipid autoantibodies in the pathogenesis of various diseases, which may facilitate the development of potential therapeutic targets for the treatment of anti-phospholipid autoantibody-related disorders.

Keywords: Anti-phospholipid autoantibodies; Autoimmune diseases; COVID-19; Cardiovascular diseases; Obstetric diseases.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Antiphospholipid
Antiphospholipid Syndrome*
Autoantibodies
Humans
Lupus Erythematosus, Systemic*
Macrophages

Substances

Autoantibodies
Antibodies, Antiphospholipid